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Klebsiella pneumoniae producing Klebsiella pneumoniae carbapenemase (KPC) has been associated with serious infections and
high mortality. The optimal antimicrobial therapy for infection due to KPC-producing K. pneumoniae is not well established.
We conducted a retrospective cohort study to evaluate the clinical outcome of patients with bacteremia caused by KPC-produc-
ing K. pneumoniae. A total of 41 unique patients with blood cultures growing KPC-producing K. pneumoniae were identified at
twomedical centers in the United States. Most of the infections were hospital acquired (32; 78%), while the rest of the cases were
health care associated (9; 22%). The overall 28-day crude mortality rate was 39.0% (16/41). In the multivariate analysis, definitive
therapy with a combination regimen was independently associated with survival (odds ratio, 0.07 [95% confidence interval,
0.009 to 0.71], P 0.02). The 28-day mortality was 13.3% in the combination therapy group compared with 57.8% in the mono-
therapy group (P 0.01). The most commonly used combinations were colistin-polymyxin B or tigecycline combined with a
carbapenem. The mortality in this group was 12.5% (1/8). Despite in vitro susceptibility, patients who received monotherapy
with colistin-polymyxin B or tigecycline had a higher mortality of 66.7% (8/12). The use of combination therapy for definitive
therapy appears to be associated with improved survival in bacteremia due to KPC-producing K. pneumoniae.
Since the initial report in 2001, Klebsiella pneumoniae that pro-duces KPC (Klebsiella pneumoniae carbapenemase)-type
-lactamase has proliferated in hospital environments in the
United States and worldwide (3, 12). KPC-producing K. pneu-
moniae is typically resistant to carbapenems as well as cephalospo-
rins and other classes of antimicrobials, leaving few choices for
treatment of infections. Mortality from infections due to KPC-
producing K. pneumoniae has been reported to be at least 50% (2,
11, 15, 18). Whereas some KPC-producing K. pneumoniae are
reported as susceptible to carbapenems, especially imipenem, the
clinical significance of this phenomenon is not well defined. A
recent report from New York City, NY, pointed out high clinical
failure rates of carbapenem monotherapy when it was given to
treat patients with KPC-producing K. pneumoniae reported to be
susceptible to imipenem or meropenem (17). However, a limita-
tion of that study and some previous studies addressing clinical
outcome in patients from whom KPC-producing K. pneumoniae
have been isolated has been distinguishing between colonization
and actual infection. To address this problem, we conducted a
retrospective cohort study to assess the clinical and microbiologic
outcome after various treatment regimens that included only pa-
tients with documented bacteremia due to KPC-producing K.
pneumoniae.
(Preliminary data were presented at the 50th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Boston,
MA, 12 to 15 September 2010 [abstr. K-614].)
MATERIALS AND METHODS
Study design and patients. Cases of bacteremia due to K. pneumoniae
were identified at twomedical centers, one in New York City, NY, and the
other in Pittsburgh, PA, between 2005 and 2009. Clinical data were col-
lected fromelectronicmedical records and deidentified for further review;
only the first episode of bacteremia was included for each patient. At least
one isolate was collected from each case for microbiologic analysis. All
ertapenem nonsusceptible K. pneumoniae isolates, as determined by ei-
ther the disk diffusion method or MicroScan (Siemens Healthcare Diag-
nostics, Deerfield, IL) based on the breakpoints at the time of the case
identification, were subjected to PCR analysis for identification of
the KPC gene (8). Only the cases whose isolates were confirmed to carry
the KPC gene were included in this analysis. The study was approved
by the institutional review boards at both participating sites.
Definitions. The source of infection leading to bacteremia was deter-
mined as pneumonia, urinary tract infection, surgical site infection, intra-
abdominal infection, line-related infection, or primary bacteremia using
the definitions by the Centers for Disease Control and Prevention (9).
Severity of illness at the time of onset of infectionwas assessed by the acute
physiology and chronic health evaluation II (APACHE II) score (14).
Immunocompromised state was defined as the presence of diabetes mel-
litus, neutropenia, HIV infection, or receipt of steroids (at least 20 mg of
prednisone or equivalent a day for at least a month) or other immuno-
suppressive agents in the 30 days prior to bacteremia. Appropriate therapy
was defined as treatment with at least one agent for at least 48 h to which
the isolate was susceptible in vitro based on the interpretative criteria from
the Clinical and Laboratory Standards Institute (CLSI) published in 2011
(6). Empirical therapy was defined as treatment given before final culture
results became available. Definitive therapy was defined as antimicrobial
therapy given after the susceptibility testing results became available, re-
gardless of the in vitro susceptibility to the agent. Combination therapy
was defined as administration of two antimicrobials with Gram-negative
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activity for at least 48 h after the susceptibility results became available,
regardless of the in vitro susceptibility to each agent.
Predictors of mortality. The primary outcome measure was death
within 28 days from the onset of bacteremia. Risk factors for mortality in
patients having bacteremia due to KPC-producing K. pneumoniae were
investigated by comparing clinical variables of patients who died within
28 days of infection against those who survived. The variables reviewed
included demographic data, admission from a nursing home, any surgery
or prior use of antimicrobials with Gram-negative activity in the prior 30
days, presence of indwelling devices at the time of infection, prior hospi-
talization, intensive care unit (ICU) admission, surgery, or dialysis in the
preceding year, length of hospital stay before the onset of bacteremia,
inappropriate empirical therapy, combination therapy for definitive
treatment, appropriate therapy at any time, ICU stay at the time of infec-
tion, the source of bacteremia, APACHE II score, immunocompromised
state, history of organ transplant, and history of various underlying dis-
eases.
Microbiologic methods. TheMICs of various antimicrobials, includ-
ing carbapenems, were determined by the broth microdilution method
using Sensititre GNX2F plates (TREK Diagnostic Systems, Cleveland,
OH). The results were interpreted according to the breakpoints published
byCLSI in 2011, which include the revised breakpoints for cephalosporins
and carbapenems for Enterobacteriaceae (6). In addition, carbapenem
MICs were determined using Etest (bioMérieux, Durham, NC) for iso-
lates of the cases treated with this group of agents.
The KPC type was determined as KPC-2 or KPC-3 for each isolate by
nucleotide sequencing using an ABI3730xl instrument (Applied Biosys-
tems, Foster City, CA). Genetic relatedness of the isolates was determined
by pulsed-field gel electrophoresis (PFGE) using SpeI (New England Bio-
Labs, Ipswich, MA).
Statistical analysis. Statistical analysis was performed by using the
SPSS statistical software (version 19; SPSS Inc., Chicago, IL). The Student
t test was used to compare the continuous variables. Categorical variables
were evaluated by using the 2 test or Fisher’s exact test, as appropriate.
Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. To
identify independent predictors of mortality, variables with a P value of
0.15 on a univariate analysis were included in a stepwise conditional
multivariate logistic regression model. All P values were two-tailed, and a
P value of0.05 was considered statistically significant.
RESULTS
A total of 41 unique cases of bacteremia with KPC-producing K.
pneumoniae were identified during the study period. The demo-
graphics and clinical characteristics of the cases are shown inTable
1. The ages of the patients ranged from 25 to 90 years, with a
median of 62 years. There were 17 male and 24 female patients.
Most of the infections (32; 78.0%) were hospital acquired, while
the rest of cases (9; 22.0%)were health care associated. There were
no community-acquired cases. All but one patient (40; 97.5%)
had been admitted to the hospital within a year prior to the epi-
sode of bacteremia, with the majority of them (28; 70%) having
been admitted to an ICU. The most common sources of infection
were an intravascular catheter (13; 31.7%), pneumonia (10;
24.4%), and urinary tract infection (7; 17.1%). The source of bac-
teremia could not be identified in 6 patients, and these cases were
defined as primary bacteremia. The majority of the patients re-
ceived inappropriate empirical antimicrobial therapy before the
susceptibility results became available (26 [63.4%] by the CLSI
2009 breakpoints prior to the revision and 32 [78.0%] by the re-
vised CLSI 2011 breakpoints).
The overall 28-day mortality was 39.0% (16/41). The results of
univariate and multivariate analyses for predictors of mortality
are shown in Table 1. In the univariate analysis, pneumonia as the
source of infection (OR, 5.7 [95% CI, 0.98 to 3.68], P  0.03),
presence of cardiovascular disease (OR, [95%CI, 1.59 to],P
0.01), and chronic liver disease (OR,  [95% CI, 0.72 to ], P 
0.05) were significantly associated withmortality, while combina-
tion therapy was strongly associated with survival (OR, 0.13 [95%
CI, 0.01 to 0.82], P  0.01). In the multivariate analysis, no risk
factor was found to be independently associated with the mortal-
ity. However, combination therapy as definitive therapy still re-
mained as an independent predictor of survival (OR, 0.07 [95%
CI, 0.009 to 0.71], P 0.02) as shown in Table 1.
We thus further analyzed the cases which received definitive
antimicrobial therapy. Seven cases were excluded from this anal-
ysis either because they did not receive any definitive antimicro-
bial therapy or received it for less than 48 h or because they died
before receiving any definitive therapy. The 28-day mortality for
the remaining 34 cases was 38.2% (13/34). Of these 34 cases, 15
patients (44.1%) received combination therapy and 19 patients
(55.9%) received monotherapy as definitive therapy. There were
no statistically significant differences between the demographics
and the clinical characteristics, including severity of illness at the
time of infection, among patients treated with combination ther-
apy or monotherapy, except that the transplant patients were
more common in the combination therapy group (Table 2).
Two of the 15 patients (13.3%) receiving combination therapy
died within 28 days of the onset of bacteremia, compared with 11
of 19 patients (57.8%) receiving monotherapy (P  0.01). The
regimens of combination therapy and monotherapy are shown in
Table 3. The most common combination regimens were a carba-
penemwith either colistin-polymyxin B (5 cases) or tigecycline (3
cases). Only 1 of these 8 patients died within 28 days. All of these 8
isolates were susceptible to colistin-polymyxin B (MIC range,
0.25 to 0.5g/ml) or tigecycline (MIC range,0.25 to 1g/ml).
For carbapenems, all 8 isolates were resistant according to the
CLSI 2011 breakpoints (6). Under the CLSI 2009 breakpoints
which were in place at the time of the cases (4), 5 were nonsuscep-
tible, while 3 were susceptible to respective carbapenems with
MICs of 4 g/ml. The isolate from the only patient who died in
this carbapenem combination group was nonsusceptible to dori-
penemwith anMICof2g/ml. In themonotherapy group, 7, 5,
and 4 patients received colistin-polymyxin B, tigecycline, or car-
bapenem, respectively. The isolates from all 7 patients who re-
ceived colistin-polymyxin B asmonotherapy hadMICs in the sus-
ceptible range of0.25 to 0.5g/ml, but the mortality was 57.1%
(4/7) nonetheless. Isolates from the 5 patients who received tige-
cycline as monotherapy also had MICs in the susceptible range
(0.25 to 0.5 g/ml) but 4 (80.0%) died. Among the 4 patients
who received carbapenem monotherapy, 3 received imipenem
(MICs, 2 to 4g/ml) and 1 of them (33.3%) died. The last patient
in the carbapenem monotherapy group received meropenem
(MIC, 8 g/ml). This patient also died within 28 days. Each of
the remaining 3 patients received ampicillin-sulbactam (resis-
tant), gentamicin (susceptible), or piperacillin-tazobactam (resis-
tant).
Table 4 shows the susceptibility of the 41 isolates, interpreted
according to the breakpoints before and after the revision. Some
KPC-producing K. pneumoniae are reported as susceptible to car-
bapenems, in particular imipenem, when automated susceptibil-
ity testing methods are used under the previous CLSI breakpoints
(5). In our series, 23 isolates (56.1%) were susceptible to imi-
penem according to the breakpoints prior to the revision. How-
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ever, only 2 (4.9%) were susceptible under the revised break-
points. When we tested the MICs of imipenem using the Etest
method against 11 isolates for which the cases were treated with
this agent, 9 isolates had MICs of 32 g/ml. This included 3
isolates that were reported as susceptible and another 3 isolates
that were reported as intermediate at the time of infection.
Twenty-one isolates produced KPC-2, while 20 produced
KPC-3. According to PFGE, the isolates were grouped into 14
pulse types using a similarity cutoff value of 85%. The two largest
pulse types had 9 and 7 isolates, all of which were from the study
site in New York City, NY. However, using a cutoff value of 75%,
36 of the 41 isolates clustered together, including isolates from
both study sites (data not shown).
DISCUSSION
KPC-producing K. pneumoniae has become a major hospital
pathogen worldwide, and infections due to this organism have
been associated with high mortality (2, 11, 15, 18). The increasing
prevalence and the high mortality associated with the organism
underscore the importance of effective antimicrobial therapy for
these serious infections. However, optimal treatment for infec-
tions caused by KPC-producing K. pneumoniae has not yet been
defined (13).
Our study involved 41 unique patients with bacteremia due to
KPC-producingK. pneumoniae. The overall 28-daymortality rate
of 39.0%, which is slightly lower than the rates reported for KPC-
producing K. pneumoniae bacteremia in previous studies (2, 18),
TABLE 1 Predictors of mortality in 41 patients with bacteremia due to KPC-producing K. pneumoniae
Variable Survived (n 25)a Died (n 16)a
Univariate analysis Multivariate analysisb
OR (95% CI) P value OR (95% CI) P value
Demographics
Caucasian 14 (56) 6 (37.5) 0.4 (0.10–2.02) 0.34
Age65 9 (36) 8 (50) 1.5 (0.35–6.44) 0.74
Male 10 (40) 7 (43) 1.1 (0.27–5.02) 1.00
APACHE II20 12 (48) 9 (56) 0.7 (0.13–4.24) 0.72
In ICU at enrollment 13 (52) 9 (56) 1.5 (0.35–6.45) 0.75
Therapy
Inappropriate empirical therapy 21 (65.6) 11 (34.3) 0.2 (0.07–2.33) 0.27
Combination definitive therapy 13 (60) 2 (12.5) 0.13 (0.01–0.82) 0.01 0.07 (0.009–0.71) 0.02
Appropriate therapy at any time 18 (78.2) 10 (62.5) 0.46 (0.08–2.35) 0.30
Source of bacteremia
Pneumonia 3 (12) 7 (43.7) 5.7 (0.98–3.68) 0.03
Line related 9 (36) 4 (25) 0.5 (0.12–2.88) 0.51
Urinary tract 5 (20) 2 (12.5) 0.5 (0.12–2.88) 0.51
Primary bacteremia 5 (20) 1 (6.2) 0.2 (0.01–2.87) 0.38
Underlying diseases
Diabetes mellitus 5 (20) 5 (31.2) 1.8 (0.35–9.67) 0.48
Chronic renal failure 5 (20) 4 (25) 1.3 (0.24–7.47) 0.72
COPDc 2 (8) 0 (0) 0.0 (0.00–6.72) 0.51
Cardiovascular 0 5 (31.2)  (1.59–) 0.01
Cerebrovascular 2 (8) 0 0.0 (0.00–6.72) 0.51
Chronic liver disease 0 3 (18.7)  (0.72–) 0.05
Malignancy 5 (20) 3 (18.7) 0.9 (0.14–5.67) 1.00
Solid organ malignancy 5 (20) 2 (12.5) 0.5 (0.06–4.16) 0.68
Transplant 7 (28) 2 (12.5) 0.3 (0.04–2.46) 0.44
HIV 2 (8) 1 (6.2) 0.7 (0.02–2.47) 1.00
Immunocompromised state 16 (64) 10 (66.6) 0.9 (0.21–4.18) 1.00
Renal dialysis 5 (20) 6 (37.5) 2.4 (0.48–12.39) 0.28
Events in prior 30 days
Prior use of antimicrobials 18 (72) 13(81.2) 1.6 (0.30–10.27) 0.71
Surgery 9 (36) 6 (37.5) 1.0 (0.24–4.73) 1.00
Events in prior year
Hospitalization 24 (96) 16 (100)  (0.03–) 1.00
Surgery 17 (68) 8 (50) 0.5 (0.10–2.05) 0.33
Admitted to ICU 18 (72) 10 (62.5) 0.6 (0.14–3.00) 0.73
Indwelling devices
Urinary catheter 9 (36) 9 (56) 2.2 (0.53–0.12) 0.33
Tracheostomy tube 12 (48) 5 (31.2) 0.4 (0.11–2.19) 0.34
Vascular catheter 18 (72) 13 (81.2) 1.7 (0.30–10.27) 0.71
Gastrostomy tube 9 (36) 7 (43.7) 1.4 (0.32–6.04) 0.75
a Data are presented as n (%).
b Combination definitive therapy, pneumonia as the source of bacteremia, chronic liver disease, and coronary artery disease were included in the multivariate analysis.
c COPD, chronic obstructive pulmonary disease.
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may reflect the increased awareness of this highly resistant organ-
ism over time and consequent early institution of active antimi-
crobial therapy. Alternatively, the differencemay be due to unrec-
ognized confounding variables. Nonetheless, the mortality still
remains considerably higher than for bacteremia due to K. pneu-
moniae not producing KPC (16).
We did not identify any independent clinical risk factor for
mortality. This may be due to the small number of cases in this
series or our failure to identify and analyze a pertinent confound-
ing risk factor. Another possibility is that 28 days is not a discrim-
inating endpoint, as by 28 days, mortality may be influenced by
underlying comorbidities. However, the use of an earlier endpoint
such as 14 days is also problematic in this patient population as
they are typically still receiving antimicrobial therapy at the time.
One intriguing observation in the univariate analysis was that
pneumonia as the source of bacteremia was associated with mor-
tality. This probably is a reflection of higher severity of illness in
this group, as manifested by a mean APACHE II score of 25 and
also the relative difficulty in controlling the source of infection
compared with other sources.
Our study demonstrated that survival in patients with KPC-
producing K. pneumoniae bacteremia was significantly improved
when combination therapy rather than monotherapy was given.
Several combinations appeared to be effective, but the most com-
mon successful combination regimens used in our patients were
either colistin-polymyxin B or tigecycline in combination with a
carbapenem. These combination regimens were more successful
than monotherapy with either colistin-polymyxin B or tigecy-
cline, even when in vitro testing confirmed susceptibility to the
respective antimicrobials. These findings are consistent with a co-
hort study on bacteremic cases recently published from Greece
(18) and also a review of case series (13), where higher clinical
failure rates were observed with monotherapy. While the mecha-
nisms underlying the effectiveness of these combinations are not
known, synergistic activity between carbapenems and colistin has
been observed in vitro among our KPC-producingK. pneumoniae
isolates, which is consistent with the clinical observation pre-
sented here, at least for this particular combination (Ryan Shields,
University of Pittsburgh Medical Center, personal communica-
tion).
In light of the concern for underdosing of colistin, we also
compared the colistin regimens (dosed as colistin base activity of
colistinmethanesulfonate) in those receivingmonotherapy versus
recently published recommendations (10). All three of these pa-
tients were dosed at the recommended frequency and received
greater total daily doses compared to these recent recommenda-
tions, even when targeting an average steady-state concentration
of 2g/ml. Furthermore, in addition to inferior clinical outcome,
monotherapy with colistin-polymyxin B has been associated with
emergence of colistin-polymyxin B resistance (1, 19). As such,
colistin-polymyxin B monotherapy needs to be employed with
caution in patients having infectionwithKPC-producingK. pneu-
moniae.
Clinical failures with carbapenem monotherapy were also fre-
quently observed in our study, which is not surprising and is con-
sistent with previous studies (7, 18). Of note, although carba-
penem treatment was inadequate asmonotherapy, the addition of
imipenem to colistin-polymyxin B or tigecycline was clearly





(n 19)a P value OR (95% CI)
Demographics
Age65 6 (40) 11 (57.8) 0.49 0.4 (0.09–2.35)
Male 8 (53.3) 7 (36.8) 0.50 1.7 (0.36–8.31)
Severity of illness
In ICU at enrollment 10 (66.6) 10 (52.6) 0.49 1.8 (0.36–9.28)
APACHE II 17.4 6.65 21.3 8.69 0.15
LOSb 35 28 34.9 72 0.99
Underlying diseases
Immunocompromised state 11 (73.3) 9 (47.3) 0.17 3.0 (0.58–17.14)
Chronic renal failure 3 (20) 3 (15.8) 1.00 1.3 (0.17–10.54)
Malignancy 3 (20) 5 (15.8) 1.00 0.7 (0.02–4.51)
Transplant 8 (53.3) 0 0.001  (3.01–)
a Data are presented as n (%) or mean standard deviation (SD).
b LOS, length of stay before bacteremia.
TABLE 3 Definitive antimicrobial therapy and mortality in 17 patients
who received combination therapy and 19 patients who received
monotherapy
Definitive treatment n (%) Mortality n (%)
Combination therapy 15 (44) 2 (13.3)
Colistin-polymyxin B combined with:
Carbapenem 5 (33) 1 (20)
Tigecycline 1 (7) 0
Fluoroquinolone 1 (7) 0
Tigecycline combined with:
Carbapenem 3 (20) 0
Aminoglycoside 2 (12) 0
Carbapenem-fluoroquinolone 1 (7) 1 (100)
Aztreonam-fluoroquinolone 1 (7) 0
Cefepime-gentamicin 1 (7) 0
Monotherapy 19 (46) 11 (57.8)
Colistin-polymyxin B 7 (36.8) 4 (57.1)
Tigecycline 5 (26.3) 4 (80)
Carbapenem 4 (21) 2 (50)
Gentamicin 1 5.2) 0
Ampicillin-sulbactam 1 (5.2) 0
Piperacillin-tazobactam 1 (5.2) 1 (100)
Total 34 (83) 13 (38.2)
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beneficial, even in patients whose isolates would now be clas-
sified as resistant to carbapenems, including imipenem. Over-
all, our data confirm that combination therapy appears to have
a significant survival benefit in patients with bacteremia due to
this organism.
Our study is limited by its observational nature and relatively
small number of cases, as we limited the analysis to cases with
bacteremia only. In addition, there were more transplant patients
in the combination therapy group than the monotherapy group.
However, given the degree of immunosuppression and underly-
ing comorbidities in this patient population, this was more likely
to underestimate, rather than overestimate, the effectiveness of
combination therapy.
In conclusion, mortality associated with bacteremia due to
KPC-producing K. pneumoniae continues to be high. The use of a
combination therapy, in particular with either colistin-polymyxin
B or tigecycline and a carbapenem, seems to have a survival benefit
in this critically ill population.
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a These isolates initially tested as intermediate in the clinical laboratories based on the CLSI 2009 breakpoints and were positive for the KPC gene by PCR and sequencing but tested
as susceptible using the manual broth microdilution method in the research laboratory.
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